FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to ...

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025Data ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

Research and Development (R&D) expenses: R&D expenses totaled $20.0 million for the first quarter of 2025. These expenses ...

ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit.

Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held this week May 13-17, at the Ernest N.

In today’s fast-paced biotechnology landscape, AMSA Biotech emerges as a trailblazer in the field of regenerative medicine. Driven by a vision of science-led healing and personalized care, the company ...

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide ...